Skip to content
Inciteful Med

Curative Options: Stem Cell Transplants and Gene Therapy

Last updated:

Stem cell transplants and gene therapies are the main curative options for beta-thalassemia major. While sibling donor transplants are the established standard, new gene therapies modify the patient's own cells to restore healthy hemoglobin production and achieve transfusion independence.

Key Takeaways

  • • Allogeneic stem cell transplantation using a matched sibling donor is the established gold standard cure for beta-thalassemia.
  • • The Pesaro scale measures liver health and iron overload to predict the safety and success of a stem cell transplant.
  • • FDA-approved gene therapies like Zynteglo and Casgevy use the patient's own stem cells, eliminating the risk of graft-versus-host disease.
  • • The ultimate goal of curative therapies is transfusion independence, meaning healthy hemoglobin levels for at least 12 months without needing a transfusion.
  • • Both transplant and gene therapy require intensive chemotherapy conditioning, which carries a high risk of permanent infertility.

While lifelong transfusions and chelation are effective, many families eventually explore options that can provide a permanent cure [1]. There are two main paths to a cure: Stem Cell Transplantation, which has been the gold standard for decades, and Gene Therapy, a revolutionary new frontier [2][1][3].

Allogeneic Stem Cell Transplant (HSCT)

An allogeneic hematopoietic stem cell transplant (HSCT) is currently the most established cure [1]. It involves replacing your child’s blood-making system with healthy stem cells from a donor [4].

  • The Gold Standard: The best results occur when the donor is a Matched Sibling Donor (MSD)—a brother or sister who has the same tissue type [1][5]. In these cases, the “thalassemia-free survival” rate can be higher than 95% [6][7].
  • The Risks: This is a major medical procedure. The primary risk is Graft-Versus-Host Disease (GVHD), where the donor’s immune cells attack the child’s body [4][8]. Other risks include severe infections and the possibility of the new cells being rejected [8][9].
  • The Pesaro Classification: Doctors use the “Pesaro scale” to predict how safe a transplant will be [10][11]. Children in Class 1 (those with the least amount of liver damage and iron overload) have the best outcomes [12][13]. This is why it is critical to manage iron carefully from day one, even if you are planning for a future cure [1][5].

Gene Therapy: The New Frontier

Gene therapy is a breakthrough because it uses the child’s own stem cells, which are removed, “fixed” in a lab, and then returned to the body [14][15]. Because the cells come from the child, there is zero risk of GVHD [14][16].

There are two main types of FDA-approved gene therapies:

  1. Gene Addition (e.g., Zynteglo): A harmless virus (called a lentiviral vector) is used to insert a working version of the beta-globin gene into the child’s stem cells [17][14].
  2. Gene Editing (e.g., Casgevy): Using “genetic scissors” called CRISPR, scientists edit the DNA to turn back on the production of fetal hemoglobin, which then does the work of carrying oxygen [15][18][19].

The Goal: Transfusion Independence

The measure of success for these therapies is transfusion independence [20]. This means the child’s hemoglobin stays at a healthy level (usually above 9.0 g/dL) for at least 12 consecutive months without needing a single blood transfusion [20][17]. In clinical trials, the vast majority of patients achieved this goal [20][21].

Important Considerations and Infertility Risks

While curative options are exciting, they are also intensive:

  • Conditioning and Fertility: Before receiving the new or edited cells, children must undergo myeloablative conditioning (strong chemotherapy) to clear out the old bone marrow [3][22]. It is crucial to know that this intensive chemotherapy carries a high risk of permanent infertility. You should discuss fertility preservation options with your medical team long before beginning the process [22].
  • Accessibility: Gene therapy is currently very expensive and only available at specialized “Qualified Treatment Centers” [3][23].
  • Monitoring: Even after a cure, your child will need long-term monitoring to ensure the new system is working and to manage any iron that was already stored in their organs [24][25].

Frequently Asked Questions

What is the best donor for a stem cell transplant in beta-thalassemia?
The best results for a stem cell transplant come from a matched sibling donor, which is a brother or sister with the exact same tissue type. This significantly increases the chances of a successful, thalassemia-free survival.
What is the Pesaro classification?
The Pesaro scale helps doctors predict the safety and success of a stem cell transplant based on a patient's liver health and iron overload history. Children with less liver damage and well-managed iron levels generally have the safest and most successful outcomes.
How does gene therapy cure beta-thalassemia?
Gene therapy works by extracting a child's own stem cells, fixing the faulty genetic code in a specialized lab, and returning the cells to the body. Because it uses the patient's own cells, there is zero risk of graft-versus-host disease.
What is the difference between Zynteglo and Casgevy?
Zynteglo uses a harmless virus to insert a working beta-globin gene into the patient's cells. Casgevy uses CRISPR gene-editing technology to alter the DNA and turn back on the production of fetal hemoglobin, which takes over the job of carrying oxygen.
Will my child be infertile after gene therapy or a stem cell transplant?
Both transplant and gene therapy require strong chemotherapy, called myeloablative conditioning, to clear out the old bone marrow before new cells are introduced. This intensive process carries a very high risk of permanent infertility, so fertility preservation should be discussed early on.

Questions for Your Doctor

  • • Based on my child's liver health and iron history, what is their 'Pesaro Risk Class'?
  • • Is there a matched sibling donor available in our family, or should we look at the registry for a matched unrelated donor?
  • • How many years of 'thalassemia-free survival' do patients typically have after a successful transplant at this center?
  • • Is my child’s specific mutation eligible for gene addition (Zynteglo) or gene editing (Casgevy)?
  • • What does the 'conditioning' process involve for my child, and what are the long-term risks to their fertility or growth?

Questions for You

  • • How do I feel about the trade-off between the lifelong management of thalassemia and the intensive, one-time risks of a transplant?
  • • Do we have the social and financial support needed for a multi-month hospital stay during the transplant process?
  • • What are my goals for my child’s quality of life (e.g., participating in sports without fatigue, ending the need for daily pills)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Curative Approach to the Treatment of Beta-Thalassemia and Sickle Cell Disease with Hematopoietic Stem Cell Transplantation.

    Testa U, Castelli G, Pelosi E

    Journal of clinical medicine 2026; (15(4)) doi:10.3390/jcm15041379.

    PMID: 41753067
  2. 2

    Hematopoietic Stem Cell Transplantation in Thalassemia.

    Algeri M, Lodi M, Locatelli F

    Hematology/oncology clinics of North America 2023; (37(2)):413-432 doi:10.1016/j.hoc.2022.12.009.

    PMID: 36907612
  3. 3

    Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy.

    Duesberg MS, Schiller G

    Cureus 2025; (17(10)):e95112 doi:10.7759/cureus.95112.

    PMID: 41281092
  4. 4

    Is the Benefit-Risk Ratio for Patients with Transfusion-Dependent Thalassemia Treated by Unrelated Cord Blood Transplantation Favorable?

    Jaing TH

    International journal of molecular sciences 2017; (18(11)) doi:10.3390/ijms18112472.

    PMID: 29156642
  5. 5

    Hematopoietic stem cell transplantation for non-malignant hematological disorders.

    Formánková R, Starý J

    Vnitrni lekarstvi 2018; (64(5)):530-536.

    PMID: 30193523
  6. 6

    G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major.

    Li Q, Luo J, Zhang Z, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(10)):2040-2044 doi:10.1016/j.bbmt.2019.06.009.

    PMID: 31207293
  7. 7

    Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical trial.

    Huang Q, Liu R, Zheng B, et al.

    Therapeutic advances in hematology 2026; (17()):20406207261416816 doi:10.1177/20406207261416816.

    PMID: 41695780
  8. 8

    Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence.

    Kuba A, Raida L

    Mediators of inflammation 2018; (2018()):9451950 doi:10.1155/2018/9451950.

    PMID: 29785172
  9. 9

    Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.

    Lüftinger R, Zubarovskaya N, Galimard JE, et al.

    Annals of hematology 2022; (101(3)):655-665 doi:10.1007/s00277-021-04732-4.

    PMID: 34999929
  10. 10

    Outcome of Haematopoietic Stem Cell Transplant in Beta-Thalassaemia Major: Single Centre Experience from a Low- and Middle-Income Country.

    Khan H, Ghafoor T, Shahbaz N, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2025; (35(4)):513-518 doi:10.29271/jcpsp.2025.04.513.

    PMID: 40235254
  11. 11

    Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial.

    Shenoy S, Walters MC, Ngwube A, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; (24(6)):1216-1222 doi:10.1016/j.bbmt.2018.01.023.

    PMID: 29374585
  12. 12

    Allogenic Hematopoietic Cell Transplantation in Thalassemia Major: A Single-center Retrospective Analysis From India.

    Choudhary D, Doval D, Sharma SK, et al.

    Journal of pediatric hematology/oncology 2019; (41(5)):e296-e301 doi:10.1097/MPH.0000000000001475.

    PMID: 30933028
  13. 13

    Hematopoietic Stem Cell Transplantation in Thalassemia Patients: a Jordanian Single Centre Experience.

    Mustafa M, Qatawneh M, Al Jazazi M, et al.

    Materia socio-medica 2020; (32(4)):277-282 doi:10.5455/msm.2020.32.277-282.

    PMID: 33628130
  14. 14

    Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.

    Inam Z, Han H, Webb J, Delaney M

    Transfusion medicine reviews 2025; (39(4)):150930 doi:10.1016/j.tmrv.2025.150930.

    PMID: 41223813
  15. 15

    Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.

    Winkler R, Herath I, Kaczmarek R, et al.

    Journal of blood medicine 2026; (17()):576017 doi:10.2147/JBM.S576017.

    PMID: 41773269
  16. 16

    Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.

    Segura EER, Ayoub PG, Hart KL, Kohn DB

    Viruses 2023; (15(3)) doi:10.3390/v15030713.

    PMID: 36992422
  17. 17

    Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.

    Locatelli F, Thompson AA, Kwiatkowski JL, et al.

    The New England journal of medicine 2022; (386(5)):415-427 doi:10.1056/NEJMoa2113206.

    PMID: 34891223
  18. 18

    β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.

    Langer AL, Esrick EB

    Hematology. American Society of Hematology. Education Program 2021; (2021(1)):600-606 doi:10.1182/hematology.2021000313.

    PMID: 34889443
  19. 19

    CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease.

    McManus M, Frangoul H, Steinberg MH

    Expert review of hematology 2024; (17(12)):957-966 doi:10.1080/17474086.2024.2429605.

    PMID: 39535263
  20. 20

    Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.

    Locatelli F, Lang P, Wall D, et al.

    The New England journal of medicine 2024; (390(18)):1663-1676 doi:10.1056/NEJMoa2309673.

    PMID: 38657265
  21. 21

    Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.

    Kwiatkowski JL, Thompson AA, Schneiderman J, et al.

    Blood 2026; doi:10.1182/blood.2025029196.

    PMID: 41525466
  22. 22

    Current and future alternative therapies for beta-thalassemia major.

    de Dreuzy E, Bhukhai K, Leboulch P, Payen E

    Biomedical journal 2016; (39(1)):24-38.

    PMID: 27105596
  23. 23

    Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.

    Kansal AR, Reifsnider OS, Brand SB, et al.

    Journal of market access & health policy 2021; (9(1)):1922028 doi:10.1080/20016689.2021.1922028.

    PMID: 34178295
  24. 24

    Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients.

    Rostami T, Monzavi SM, Poustchi H, et al.

    International journal of hematology 2021; (113(1)):145-157 doi:10.1007/s12185-020-02998-4.

    PMID: 33033952
  25. 25

    Correlation of Transient Elastography With MRI T2* and Serum Ferritin Levels in Children With Transfusion-Dependent Thalassemia.

    Parakh N, Chandra J

    Indian pediatrics 2022; (59(12)):929-932.

    PMID: 36511206

This page discusses beta-thalassemia curative options for educational purposes only. Always consult a pediatric hematologist or transplant specialist to discuss your child's specific medical situation and treatment eligibility.

Stay up to date

Get notified when new research about Beta-thalassemia major is published.

No spam. Unsubscribe anytime.